Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 10/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.38 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460094 | 0.81 | SMN1; SMN2 (0.62) | LMNASMN1; SMN2 | |
| SCHEMBL15235889 | 0.78 | CYP17A1 (0.39) | — | |
| SCHEMBL1897260 | 0.77 | HIF1A (0.55) | CD274CNR2CNR1SMN1; SMN2HIF1A | |
| SCHEMBL1812122 | 0.77 | HIF1A (0.54) | CD274CNR2HIF1AEPAS1CACNA1B | |
| SCHEMBL28429632 | 0.76 | SMN1; SMN2 (0.41) | ENPP2CNR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28784556 | 0.76 | SMN1; SMN2 (0.41) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL22571323 | 0.75 | CD274 (0.61) | CD274MEN1LMNAMAPTKMT2A | |
| SCHEMBL31242804 | 0.73 | LMNA (0.43) | CD274KDM4EMEN1LMNAMAPT | |
| SCHEMBL465864 | 0.73 | SIRT1 (0.54) | ENPP2CD274CNR2KMT2ASMN1; SMN2 | |
| SCHEMBL28784554 | 0.73 | SMN1; SMN2 (0.38) | CNR2CNR1SMN1; SMN2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| EP-2182986-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2170892-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | ENPP2 841/4885CD274 2264/4885CNR2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.